0.8181

4.52% -0.0387

After Hours: .83 0.0119 +1.45%

Mainz Biomed N.V. (MYNZ)

Overview News Price History Why MYNZ Down? Discussions Forecast

Mainz Biomed N.V. stock is currently priced at $0.8181, with a 24-hour trading volume of 306.58K. It has seen a -4.52% decreased in the last 24 hours and a -19.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.9156 pivot point. If it approaches the $0.7512 support level, significant changes may occur.

Previous Close:

$0.8568

Open:

$0.85

24h Volume:

306.58K

Market Cap:

$17.91M

Revenue:

$895.50K

Net Income/Loss:

$-26.30M

P/E Ratio:

-0.4283

EPS:

-1.91

Net Cash Flow:

$-23.84M

1W Performance:

-9.60%

1M Performance:

-19.00%

6M Performance:

-59.90%

1Y Performance:

-76.36%

1D Range:

$0.78

$0.8794

52W Range:

$0.78

$6.00

Mainz Biomed N.V. Stock (MYNZ) Company Profile

Name

Mainz Biomed N.V.

Sector

Healthcare (1191)

Industry

Diagnostics & Research (66)

Phone

49 6131 554 2860

Address

Robert Koch Strasse 50, Mainz

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

MYNZ's Discussions on Twitter

Mainz Biomed N.V. Stock (MYNZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-21-22	Initiated	H.C. Wainwright	Buy

Mainz Biomed N.V. Stock (MYNZ) Latest News

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

GlobeNewswire Inc.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Mainz Biomed Reports Full Year 2023 Financial Results

GlobeNewswire Inc.

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

GlobeNewswire Inc.

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

GlobeNewswire Inc.

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

GlobeNewswire Inc.

Mainz Biomed N.V. Stock (MYNZ) Financials Data

Mainz Biomed N.V. (MYNZ) Revenue 2024

MYNZ reported a revenue (TTM) of $895.50 thousand for the quarter ending December 31, 2023, a +68.99% rise year-over-year.

Mainz Biomed N.V. (MYNZ) Net Income 2024

MYNZ net income (TTM) was -$26.30 million for the quarter ending December 31, 2023, a +0.35% increase year-over-year.

Mainz Biomed N.V. (MYNZ) Cash Flow 2024

MYNZ recorded a free cash flow (TTM) of -$23.84 million for the quarter ending December 31, 2023, a -54.51% decrease year-over-year.

Mainz Biomed N.V. (MYNZ) Earnings per Share 2024

MYNZ earnings per share (TTM) was -$1.64 for the quarter ending December 31, 2023, a +10.38% growth year-over-year.

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.